October 20, 2008 – TomoTherapy Inc. said it has signed a letter of intent with Hitachi Medical Corp. (HMC) to distribute the im treatment system in Japan.
Terms of the agreement between TomoTherapy and HMC are being finalized. The partnership between TomoTherapy and Hitachi Medical Corporation is expected to commence by the end of 2008.
For more information: www.tomotherapy.com
July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...
July 09, 2024 
March 14, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...
March 14, 2022 
October 22, 2021 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...
October 22, 2021 
October 27, 2020 — A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical ...
October 27, 2020 
June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...
June 10, 2020 
April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...
April 16, 2020 
January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down ...
January 29, 2020 
Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact System. This new feature adds intrafraction motion synchronization capabilities to the Radixact System, enabling real-time tracking, visualization and correction for tumor motion during treatment, with the goal of improving dose accuracy and treatment times compared to conventional radiation therapy systems. The Radixact System with Synchrony will be unveiled at the European Society for Radiotherapy & Oncology (ESTRO) meeting, April 26-30 in Milan, Italy.
April 24, 2019 
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with hypofractionated intensity modulated radiation therapy (HIMRT) yields equivalent disease outcomes compared with conventional intensity modulated radiation (CIMRT). It is the largest randomized single-institution study with the longest follow-up period on this topic to date.
October 31, 2018 
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton therapy solution in Japan. The first installation took place at the Hokkaido Ohno Memorial Hospital in Sapporo and the other at the Narita Memorial Proton Center in Toyohashi. Both installations were successful, according to the company, as the Hokkaido Ohno Memorial Hospital installation took less than 12 months and the Narita Memorial Proton Center installation took less than 11 months.
July 30, 2018